Study Title

Quantification With Lutetium-177 on Cadmium-Zinc-Telluride Camera 3D

Study Details

Description:

The main of this study is to demonstrate the feasibility of carrying out quantitative acquisitions regardless of the energy peak considered (113 keV (kiloelectronVolts) or 208 keV or a combination of the 2 energy peaks). A study on phantom will optimise the reconstruction parameters. These parameters will then be applied to a population of patients who have already benefited from a recording on a 3D CZT camera (retrospective data).

Sponsor:

Central Hospital, Nancy, France

Contacts:

Véronique ROCH, MSc

v.roch@chru-nancy.fr

0383154276 ext +33

Laetitia IMBERT, PhD

l.imbert@chru-nancy.fr

0383157879 ext +33

Drug Details

Isotope(s):
    LUTETIUM-177
    Radioisotope: Lu-177
    Theranostic Role: Therapeutic Agent & SPECT Imaging
    T1/2 (Half-Life): 6.7 Days
    Decay Mode: BETA, GAMMA
    Energy: Eβeta max 497 keV, Gamma 113-208 keV
    Range: In Tissue: 0.25-2mm
    Decay Daughters: Hf177
    Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
  • LUTETIUM-177
Target(s):
  • PSMA
XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468